Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$468.63 USD

468.63
827,133

-9.21 (-1.93%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $468.63 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Add McKesson (MCK) to Your Portfolio Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.

Here's Why You Should Retain Cardinal Health (CAH) Stock Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio.

PerkinElmer (PKI) Boosts Testing Portfolio With New Solutions

by Zacks Equity Research

PerkinElmer's (PKI) introduction of two comprehensive solutions is likely to strengthen its COVID-19 testing portfolio further.

BD (BDX), ImageMover Partner for Rapid Antigen Test Reporting

by Zacks Equity Research

BD (BDX) collaborates with ImageMover to streamline rapid antigen testing results performed on the BD Veritor Plus System.

Hologic (HOLX) Partners With Gallup on Women's Health Index

by Zacks Equity Research

Hologic (HOLX) is working to develop a global women's health index through Gallup's World Poll to improve quality of life and life expectancy of women worldwide.

Abbott (ABT) Launches Telehealth Tool for Neuromodulation

by Zacks Equity Research

Abbott (ABT) stated that Medicare will cover remote programming services as a telehealth benefit through the duration of the public health emergency.

QIAGEN (QGEN) Rides on Test Launches Amid COVID-19 Woes

by Zacks Equity Research

QIAGEN (QGEN) expands specimen types that can be used on the existing NeuMoDx SARSCoV-2 test.

Myriad Genetics (MYGN) Collaborates to Advance Oncology Care

by Zacks Equity Research

Myriad Genetics (MYGN) to provide a comprehensive offering utilizing germline genetic testing and somatic tumor profiling via latest collaboration with Intermountain Precision Genomics.

Why Is Idexx (IDXX) Up 2.6% Since Last Earnings Report?

by Zacks Equity Research

Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

National Vision (EYE) Q4 Earnings Top Estimates, Margins Up

by Zacks Equity Research

National Vision (EYE) witnesses comparable growth on increased customer transaction in Q4.

Medtronic's (MDT) REVERSE Trial Indicates CRT's Benefits for HF

by Zacks Equity Research

Medtronic's (MDT) REVERSE analysis highlights the role played by CRT to slow the progression of HF, thus reinforcing the strong clinical evidence supporting CRT.

Here's Why You Should Hold on to Medtronic (MDT) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Medtronic (MDT) on slew of product launches and regulatory approvals.

Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (IDXX) Outperforming Other Medical Stocks This Year?

Hologic (HOLX) Boosts Diagnostics Portfolio With New Buyout

by Zacks Equity Research

Hologic (HOLX) strengthens international capabilities and expands diagnostics arm across test menu, customer segments and geography with recent acquisition.

Here's Why You Should Add Abbott (ABT) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Abbott (ABT) due to a slew of product launches and regulatory approvals.

Orthofix's (OFIX) Q4 Earnings Top Estimates, Margin Declines

by Zacks Equity Research

Orthofix (OFIX) registers improvement in Global Spine segment's revenues during Q4 due to strength in its spinal implants portfolio.

Teleflex (TFX) Beats on Q4 Earnings and Revenues, Margins Fall

by Zacks Equity Research

Teleflex (TFX) witnesses significant sequential improvement in segmental performance during the fourth quarter on gradual recovery of the economy.

NuVasive's (NUVA) Q4 Earnings Top Estimates, Margin Declines

by Zacks Equity Research

NuVasive (NUVA) registers strong international performance in Q4 along with continued adoption of advanced material science implants in the U.S. Spinal Hardware business.

Tandem Diabetes' (TNDM) Q4 Earnings, Revenues Top Estimates

by Zacks Equity Research

Tandem Diabetes' (TNDM) strong domestic and international pump sales and shipments boosted the Q4 top line.

Myriad Genetics (MYGN) Beats on Q2 Revenues, Earnings in Line

by Zacks Equity Research

Myriad Genetics' (MYGN) sales in majority of the operating segments improved in the quarter despite pandemic-led business challenges.

Insulet (PODD) Q4 Earnings Fall Shy of Estimates, Revenues Beat

by Zacks Equity Research

Insulet's (PODD) Q4 revenues were significantly boosted by the robust adoption of Omnipod DASH and a growing customer base.

BD (BDX), Scanwell Health Collaborate on At-Home Coronavirus Test

by Zacks Equity Research

BD (BDX) plans to develop a lateral flow antigen test and pair it with the Scanwell Health mobile app via the latest partnership.

Here's Why You Should Add Hologic (HOLX) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Hologic (HOLX) due to a slew of product launches.

Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for DEF

Syneos Health (SYNH) Posts In-Line Q4 Earnings, Margins Up

by Zacks Equity Research

Syneos Health (SYNH) registers sales decline in both its business segments due to slower recovery in reimbursable out-of-pocket expenses across both segments.